Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
TOKYO, May 11, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today confirmed that the Court of Appeals for the Federal Circuit (CAFC) issued a Mandate that officially ends the CAFC appeal on patent infringement of LEXISCAN® (regadenoson injection) 0.4 mg/mL.
On May 3, 2023, the CAFC denied our petitions for rehearing and rehearing en banc of the CAFC’s December 30, 2022 Opinion that affirmed the U.S. District Court for the District of Delaware’s earlier decision that all asserted claims of the patents for LEXISCAN® are not infringed by Hospira, Inc.
Astellas has already reflected the impact from this decision in its financial forecast of the current fiscal year ending March 31, 2024.
Click below for a copy of the full press release
Follow us
